Diagnosis & Disease Information

Adding nivolumab to treatment with SABR improved the 4-year event-free survival rate in a phase 2 trial of patients with NSCLC.

Tepotinib plus osimertinib has demonstrated efficacy in advanced, EGFR-mutant, MET-amplified NSCLC that progressed on first-line osimertinib.

Perioperative durvalumab does not adversely impact surgical outcomes in patients with resectable non-small cell lung cancer, results from the AEGEAN trial suggest.

First-line treatment with serplulimab plus chemotherapy improves survival over chemotherapy alone in patients with advanced squamous NSCLC, a phase 3 trial suggests.

Adagrasib has shown durable clinical activity in patients with advanced KRAS^G12C-mutant NSCLC, according to updated results from the KRYSTAL-1 trial.

Patritumab deruxtecan (HER3-DXd) is effective in patients with previously treated, EGFR-mutant NSCLC, a phase 2 study suggests.

Osimertinib and chemotherapy is more effective than osimertinib alone as first-line treatment for patients with EGFR-mutant, advanced NSCLC, phase 3 data suggest.

Iruplinalkib, a novel ALK inhibitor, was more effective than crizotinib in a phase 3 trial of patients with advanced, ALK-positive non-small cell lung cancer.